Cargando…

Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects

The glycine transporter-1 inhibitor Org25935 is a promising candidate in a treatment concept for alcohol use disorder targeting the glycine system. Org25935 inhibits ethanol-induced dopamine elevation in brain reward regions and reduces ethanol intake in Wistar rats. This study aimed to further char...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lidö, Helga Höifödt, Jonsson, Susanne, Hyytiä, Petri, Ericson, Mia, Söderpalm, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2017
Materias:	Psychiatry and Preclinical Psychiatric Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399095/ https://www.ncbi.nlm.nih.gov/pubmed/28161754 http://dx.doi.org/10.1007/s00702-017-1685-z

Ejemplares similares

A Role for Accumbal Glycine Receptors in Modulation of Dopamine Release by the Glycine Transporter-1 Inhibitor Org25935
por: Lidö, Helga Höifödt, et al.
Publicado: (2011)

Effects of systemic glycine on accumbal glycine and dopamine levels and ethanol intake in male Wistar rats
por: Olsson, Yasmin, et al.
Publicado: (2020)

The glycine-containing dipeptide leucine-glycine raises accumbal dopamine levels in a subpopulation of rats presenting a lower endogenous dopamine tone
por: Olsson, Yasmin, et al.
Publicado: (2022)

Synergistic Control of Transmitter Turnover at Glycinergic Synapses by GlyT1, GlyT2, and ASC-1
por: Eulenburg, Volker, et al.
Publicado: (2022)

MS Binding Assays for Glycine Transporter 2 (GlyT2) Employing Org25543 as Reporter Ligand
por: Ackermann, Thomas M., et al.
Publicado: (2020)

An acetylcholine‐dopamine interaction in the nucleus accumbens and its involvement in ethanol's dopamine‐releasing effect
por: Loftén, Anna, et al.
Publicado: (2020)

Acute and chronic modulation of striatal endocannabinoid‐mediated plasticity by nicotine
por: Adermark, Louise, et al.
Publicado: (2018)

GlyT2+ Neurons in the Lateral Cerebellar Nucleus
por: Uusisaari, Marylka, et al.
Publicado: (2009)

Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model
por: Mohammadzadeh, Amir, et al.
Publicado: (2021)

Glycinergic transmission: glycine transporter GlyT2 in neuronal pathologies
por: Zafra, Francisco, et al.
Publicado: (2016)

Calnexin-Assisted Biogenesis of the Neuronal Glycine Transporter 2 (GlyT2)
por: Arribas-González, Esther, et al.
Publicado: (2013)

Bidirectional Modulation of Nociception by GlyT2(+) Neurons in the Ventrolateral Periaqueductal Gray
por: Assareh, Neda, et al.
Publicado: (2023)

The presynaptic glycine transporter GlyT2 is regulated by the Hedgehog pathway in vitro and in vivo
por: de la Rocha-Muñoz, Andrés, et al.
Publicado: (2021)

Membrane cholesterol regulates inhibition and substrate transport by the glycine transporter, GlyT2
por: Frangos, Zachary J, et al.
Publicado: (2023)

Identification of a 3(rd) Na(+) Binding Site of the Glycine Transporter, GlyT2
por: Subramanian, Nandhitha, et al.
Publicado: (2016)

Glycinergic Transmission in the Presence and Absence of Functional GlyT2: Lessons From the Auditory Brainstem
por: Brill, Sina E., et al.
Publicado: (2021)

Impact of the COVID-19 lockdown on screen media use in patients referred for ADHD to child and adolescent psychiatry: an introduction to problematic use of the internet in ADHD and results of a survey
por: Werling, Anna Maria, et al.
Publicado: (2021)

Betrayed by the nervous system: a comparison group study to investigate the ‘unsafe world’ model of selective mutism
por: Melfsen, Siebke, et al.
Publicado: (2021)

Three-way interaction effects of early life stress, positive parenting and FKBP5 in the development of depressive symptoms in a general population
por: Keijser, Rebecka, et al.
Publicado: (2021)

Impact of the COVID-19 pandemic on mental health and family situation of clinically referred children and adolescents in Switzerland: results of a survey among mental health care professionals after 1 year of COVID-19
por: Werling, Anna Maria, et al.
Publicado: (2022)

Genes and hormones of the hypothalamic–pituitary–adrenal axis in post-traumatic stress disorder. What is their role in symptom expression and treatment response?
por: Fischer, Susanne, et al.
Publicado: (2021)

Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder
por: Grünblatt, Edna, et al.
Publicado: (2019)

Altered urinary tetrahydroisoquinoline derivatives in patients with Tourette syndrome: reflection of dopaminergic hyperactivity?
por: Capetian, Philipp, et al.
Publicado: (2020)

Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study
por: Leplow, Bernd, et al.
Publicado: (2023)

Growth rates of human induced pluripotent stem cells and neural stem cells from attention-deficit hyperactivity disorder patients: a preliminary study
por: Yde Ohki, Cristine Marie, et al.
Publicado: (2023)

Startle disease in Irish wolfhounds associated with a microdeletion in the glycine transporter GlyT2 gene
por: Gill, Jennifer L., et al.
Publicado: (2011)

PKC-Dependent GlyT1 Ubiquitination Occurs Independent of Phosphorylation: Inespecificity in Lysine Selection for Ubiquitination
por: Barrera, Susana P., et al.
Publicado: (2015)

Correction: Identification of a 3(rd) Na(+) Binding Site of the Glycine Transporter, GlyT2
por: Subramanian, Nandhitha, et al.
Publicado: (2016)

The GlyT1 Inhibitor Bitopertin Ameliorates Allodynia and Hyperalgesia in Animal Models of Neuropathic and Inflammatory Pain
por: Armbruster, Anja, et al.
Publicado: (2018)

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
por: Rosenbrock, Holger, et al.
Publicado: (2018)

Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics
por: Mostyn, Shannon N, et al.
Publicado: (2019)

Sex differences in pharmacological treatment of major depressive disorder: results from the AMSP pharmacovigilance program from 2001 to 2017
por: Seifert, Johanna, et al.
Publicado: (2021)

Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001–2017
por: Seifert, Johanna, et al.
Publicado: (2022)

Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trial
por: Strube, Wolfgang, et al.
Publicado: (2022)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
por: Rosenbrock, Holger, et al.
Publicado: (2023)

Efficacy and safety of the novel GlyT1 inhibitor BI 425809 in Alzheimer’s dementia: a randomized controlled trial
por: Wunderlich, Glen, et al.
Publicado: (2023)

Functional connectivity during cognitive control in children with autism spectrum disorder: an independent component analysis
por: Ambrosino, S., et al.
Publicado: (2014)

Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning
por: Krysta, Krzysztof, et al.
Publicado: (2014)

Depressiveness, symptoms of anxiety and cognitive dysfunctions in patients with asthma and chronic obstructive pulmonary disease (COPD): possible associations with inflammation markers: a pilot study
por: Bratek, Agnieszka, et al.
Publicado: (2014)

Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes
por: Kovacs, David, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qc0e0u6lks9lf79k8srr569v3i